Malignant pleural effusion (MPE) accompanying lung adenocarcinoma indicates poor
prognosis and early metastasis. This study aimed to identify genes related to MPE formation …

Rationale: Non–small-cell lung cancer (NSCLC)–associated malignant pleural effusions
(MPEs) are sometimes the only available specimens for molecular analysis. Objectives: This …

Background Recurrent malignant pleural effusion (MPE) resulting from non‐small‐cell lung
cancer (NSCLC) is easily refractory to conventional therapeutics and lacks predictive …

Malignant pleural effusion (MPE) can accompany advanced lung adenocarcinoma. Recent
studies suggest that MPE could contain a heterogeneous subpopulation of cells with stem …

Background Metastasis occurs in a series of discrete steps involving invasion, angiogenesis,
lymphovascular space permeation, and establishment of secondary tumors. Malignant …

Malignant pleural effusions (MPE) commonly result from malignant tumors and represent
advanced-stage cancers. Thus, in clinical practice, early recognition of MPE is valuable …

Background Malignant pleural effusion (MPE) represents advanced malignant disease with
poor prognosis. To date, pleural effusion cytology remains the best test to diagnose MPE but …

Introduction: Pleural effusion is frequently observed in patients with advanced lung cancer.
Although effusion can be obtained less invasively and repeatedly, its use in multiplexed …

Malignant pleural effusions (MPEs) often develop in advanced cancer patients and confer
significant morbidity and mortality. In this review, we evaluated whether molecular profiling …

Lung cancer remains the most common fatal malignancy, despite more aggressive
therapies. Few patients will survive 5 years, as up to 80% of the patients will present with …